Financial Data and Key Metrics Changes - The company reported a revenue of $3,600,000,000, an increase of 8.3% compared to the previous year [12][9] - Underlying EBITDA reached $95,200,000, up $2,800,000 or about 3% year-on-year [13][12] - Net profit after tax was $31,200,000, with a statutory result of $20,600,000 [9][10] - Free operating cash flow was negative at $11,000,000, significantly impacted by receivables from a group of pharmacies [19][20] Business Line Data and Key Metrics Changes - Revenue from Australia and New Zealand grew to $3,500,000,000, an increase of 8% [21] - Gross margin in Australia and New Zealand was $277,900,000, up 5% [21] - The Asian market saw revenue increase from $84,200,000 to $101,000,000, a growth of 20% [23] Market Data and Key Metrics Changes - Strong growth was noted in Thailand's aesthetics division, contributing to the overall revenue increase in Asia [24] - The imaging business performed solidly despite some market headwinds [24] - Modest growth was observed in the Philippines due to declining contracts [24] Company Strategy and Development Direction - The company aims to continue its growth strategy in Asia following the merger with Paragon Care Group [2][4] - Focus on operational efficiencies and integration of businesses onto a single platform [26][29] - Emphasis on organic growth through investments in sales teams and new business opportunities in dental, robotics, and aesthetics [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $12,000,000 in synergies for FY '26, building on the $5,000,000 achieved in FY '25 [26][30] - The competitive landscape in retail pharmacy is evolving, with expectations for continued growth despite challenges [34][35] - Future profitability is expected to improve as synergies are realized and new opportunities are explored [30] Other Important Information - The company completed a refinancing with Scott Pak, increasing local borrowing capacity and reducing interest costs [19][20] - The acquisition of AHP Dental is expected to provide a step into the dental market, with an anticipated EBITDA contribution of around $1,000,000 for FY '26 [46][45] Q&A Session Summary Question: Outlook on revenue and profit for next year - Management indicated that revenue growth would be positive but not necessarily at the same rate as FY '25, suggesting single mid-digit growth rates [33] Question: Competitive landscape in retail pharmacy - Management noted the difficulty in predicting the competitive landscape due to market evolution, particularly following significant mergers [34] Question: Clarification on integration costs in EBITDA - Integration costs were clarified to be excluded from the underlying EBITDA figure [36][37] Question: M&A pipeline and net debt to EBITDA ratio - Management expressed willingness to increase net debt to pursue opportunities, particularly in Asia [38] Question: Details on synergies and cost savings from refinancing - Management confirmed that the $2,000,000 cost saving from refinancing is separate from the $12,000,000 synergy target for FY '26 [43][44] Question: Profitability of recent acquisitions - The AHP Dental acquisition is expected to contribute modestly to EBITDA but offers growth potential in the dental market [46] Question: Focus on growth opportunities in Asia - Management confirmed ongoing efforts to explore acquisitions in Asia that align with current operations [49] Question: Future financing arrangements with Scott Pak - Management indicated a commitment to maintaining the lowest possible cost of funds and flexibility in financing arrangements [57][58]

Financial Performance - ParagonCare achieved revenue of over $3.6 billion in FY25[31, 51, 53], reflecting an 8.3% increase in underlying revenue compared to the proforma FY24[55] - Underlying EBITDA reached $95.2 million in FY25[31, 52], a 3% increase from the proforma FY24[55] - Underlying Net Profit After Tax (excluding PPA) was $31.2 million in FY25[52, 55], representing a 9.5% increase compared to the proforma FY24[55] - Statutory EBITDA increased significantly by 97.5% to $88.5 million in FY25[53, 55], while Statutory Net Profit After Tax increased by 151.2% to $20.6 million[53, 55] Business Segments - Wholesale sales contributed $3.0 billion to the revenue, showing an 8% increase[56] - Medical Technology sales reached $298 million, a 1% increase[57] - Contract Logistics sales grew by 25% to $336 million[60, 63] - Clinical Manufacturing sales increased by 9% to $25 million[60] - Pharmacy sales grew by 11.6%, with retail pharmacy growth outpacing the market at 23.4%[58] Strategic Initiatives and Integration - The company is executing a "3-2-1" strategic initiative (Three Businesses, Two Years, One Team) to integrate merged businesses[44, 46, 87] - The company achieved $5 million in annual synergies in FY25 and is on track for $12 million in FY26[69, 85] - The company is integrating various entities onto the JDE ERP system, with completion across ANZ expected by the end of FY26[45] Balance Sheet and Cash Flow - Net debt increased to $214.8 million[55], with a Net Debt: EBITDA ratio of 2.26x[55] - Operating cash flows were impacted by a $57 million receivable from a retail pharmacy group[73] - The company secured a revised $400 million debt facility with ScotPac[48, 71] Asia Pacific (APAC) Region - Asia's total revenue from Medical Technology grew by 20% to $101.3 million[81] - The Aesthetics business drove growth in Asia due to new products and increased promotional activity[82]